The FDA granted breakthrough therapy designation to venetoclax in combination with azacitidine for treatment of certain patients with myelodysplastic syndrome.The designation applies to adults ...

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for decitabine/cedazuridine plus venetoclax to treat adults with newly diagnosed acute myeloid leukemia ...

Adding venetoclax to decitabine-cedazuridine significantly enhanced response rates in patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia. April 11th 2025 ...

Their findings (“Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy”), published in Nature Medicine, could have significant ...

Background: The prognosis of patients with higher-risk (HR) MDS after hypomethylating agent (HMA) failure is poor with a survival of 4-6 months (Garcia-Manero et al, Lancet Oncology 2016). The ...

June 18th 2025. Shorter venetoclax durations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) yielded comparable survival outcomes in a new study, challenging ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of venetoclax remain unchanged.

Phase 3 Trial Evaluating Venetoclax, Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes Jonathan Goodman, MPhil June 7, 2021 ...

Importantly, these findings indicate that treatment with venetoclax induces the death of stem cells in one of the MDS groups. The majority of MDS cases do not respond to current therapies or relapse.

Healio spoke with David Andrew Sallman, MD, about treatments in the pipeline and ongoing research in myelodysplastic syndrome. ... This is azacitidine venetoclax versus azacitidine magrolimab.

AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival. The ...

More information: Simona Colla, Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy, Nature Medicine (2022). DOI: 10.1038/s41591 ...